Correspondence

Government response to 3 medicines reports

This response agrees with recommendations from the Advisory Council on the Misuse of Drugs (ACMD) in 3 reports about the control and scheduling of 5 medicines.

From:
Advisory Council on the Misuse of Drugs
Published
23 February 2026

Documents

Government response to 3 ACMD reports (accessible)

HTML

Government response to 3 ACMD reports

PDF, 259 KB, 3 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The government accepts the ACMD’s recommendations in relation to the classification and scheduling of the 5 medicines featured in the ACMD’s reports:

The ACMD recommended that:

  • the 3 growth hormones somapacitan, lonapegsomatropin, and somatrogon should be controlled under Class C of the Misuse of Drugs Act 1971 and scheduled under Schedule 4 (Part 2) to the Misuse of Drugs Regulations 2001

  • ganaxolone, a neuroactive steroid to treat a rare form of epilepsy, should not be controlled under the Misuse of Drugs Act 1971 nor scheduled under the Misuse of Drugs Regulations 2001 at this time

  • zuranolone, an oral, synthetic neuroactive steroid (NAS) with rapid antidepressant effects used to treat post natal depression, should be controlled under Class C of the 1971 Act and scheduled under Schedule 4, (Part I) of the 2001 Regulations

Updates to this page

Published 23 February 2026

Sign up for emails or print this page